Induction of CD8 ⁺ Cells Able To Suppress CCR5-Tropic Simian Immunodeficiency Virus SIVmac239 Replication by Controlled Infection of CXCR4-Tropic Simian-Human Immunodeficiency Virus in Vaccinated Rhesus Macaques

Extralymphoid CD8 + T Cells Resident in Tissue from Simian Immunodeficiency Virus SIVmac239Δnef-Vaccinated Macaques Suppress SIVmac239 Replication Ex Vivo

“…Furthermore, we also measured very low frequencies of SIV-specific responses in the blood by tetramer analysis. Additional studies have also reported the use of viral suppression assays to demonstrate the importance of CD8 ϩ T-cell function after vaccination with SIVmac239⌬nef, SIVmac239⌬3, and simian-human immunodeficiency virus (SHIV) in rhesus macaques (13,50) and SIVmac251 challenge in cynomolgus macaques (11). In contrast to our experiments, these assays reported viral suppression after vaccination by PBMC CD8 ϩ T cells.…”

Polyfunctional CD4 + T-Cell Induction in Neutralizing Antibody-Triggered Control of Simian Immunodeficiency Virus Infection

“…We then examined, by in vitro viral-suppression assays (13,27,46,51), whether the CD8 ϩ cells from these NAb-immunized macaques had the potential to control SIV replication more efficiently than those from the controls (Fig. 7).…”

“…We examined SIVmac239 replication on CD8-depleted PBMCs in the presence of CD8 ϩ cells positively selected from PBMCs as described previously (46). In brief, PBMCs were separated into CD8 ϩ cells and CD8 Ϫ cells by using Macs CD8 MicroBeads (Miltenyi Biotec, Tokyo, Japan).…”

Prevalence of specific neutralizing antibodies against Sendai virus in populations from different geographic areas: Implications for AIDS vaccine development using Sendai virus vectors

“…13,14 SeV is pathogenic in mice, but is not known to cause disease in humans; SeV is now being developed as a xenotropic vaccine administered intranasally to prevent hPIV-1 infection or disease, and also as a delivery system (vector) for antigens from other human viruses including hPIV-3, 15 hPIV-2, 16 and RSV [17][18][19][20] and more recently for HIV. [21][22][23][24] SeV is also used as a vector to deliver human fibroblast growth factor 2, 25 and angiopoietin-1, 26 genes for the treatment of peripheral artery disease, oncolytic virotherapy, 27 and cancer immunotherapy. 28,29 SeV is widely recognized as a biological tool for delivery of reprogramming genes to generate induced pluripotent stem (iPS) cells with improved safety and efficiency that are free of vector and of chromosomal damage.…”